FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a composition for reducing inflammation for administration to a subject, comprising a repair system activator, a methyl donor and an antioxidant protection activator, where the repair system activator is nicotinamide mononucleotide (NMN); methyl donor is betaine and antioxidant protection activator is selected from H2O2, NaSH and/or zinc.
EFFECT: normalization of functions of biological pathways for protection against and elimination of disorders arising as a result of human aging is proposed.
30 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR REDUCING BIOLOGICAL AGE | 2019 |
|
RU2738644C2 |
| CELL PROCESS MODULATORS AND COMPOSITIONS BASED ON THEM FOR PREVENTING DEVELOPMENT OF AGE-RELATED DISEASES | 2023 |
|
RU2819911C1 |
| NEW USE OF NICOTINAMIDE MONONUCLETIDE (NMN) AND NICOTINAMIDE RIBOSIDE (NR) | 2020 |
|
RU2822512C2 |
| COMPOSITIONS COMPRISING A SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MILK THISTLE EXTRACT OR POWDER | 2013 |
|
RU2666953C2 |
| COMPOSITIONS CONTAINING SULFORAPHANE OR SULFORAPHANE PRECURSOR AND EXTRACT OR POWDER OF MILK THISTLE | 2013 |
|
RU2785683C2 |
| CHROMENONE ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2527269C2 |
| GEROPROTECTIVE FEED ADDITIVE | 2021 |
|
RU2770470C1 |
| QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS | 2009 |
|
RU2519779C2 |
| TYROSINE INHIBITORS WITH IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN NEONATAL KERATINOCYTE PROGENOUS CELLS | 2020 |
|
RU2809007C2 |
| COMPOSITIONS CONTAINING SULFORAPHANE OR PRECURSOR OF SULFORAPHANE AND MUSHROOM EXTRACT OR POWDER | 2013 |
|
RU2680387C2 |
